ADOPTED REGULATION OF THE

STATE BOARD OF PHARMACY

LCB File No. R187-03

Effective April 8, 2004

EXPLANATION – Matter in ***italics*** is new; matter in brackets **[**~~omitted material~~**]** is material to be omitted.

AUTHORITY: §1, NRS 454.213 and 639.070.

A REGULATION relating to pharmacy; prescribing the requirements for a program of instruction and training for a pharmacist who administers immunizations consisting exclusively of live attenuated influenza vaccine through the nasal passages of a person; and providing other matters properly relating thereto.

Section 1. NAC 639.2973 is hereby amended to read as follows:

639.2973 ***1.*** Before a pharmacist may enter into a written protocol with a physician to administer immunizations, the pharmacist must be trained and certified to administer immunizations by completing a course provided by the ***Nevada College of Pharmacy, the*** University of Nevada School of Medicine or a provider approved by the American Council on Pharmaceutical Education that includes:

[~~1.~~**]** ***(a)*** Certification in life-saving techniques pursuant to the American Heart Association's Basic Cardiac Life Support for Health Care Providers or its equivalent;

[~~2.~~**]** ***(b)*** Education and practical training, including, without limitation, written study materials regarding techniques for administering immunizations;

~~[3.]~~ ***(c)*** Evaluation of the knowledge and technique of the pharmacist in administering immunizations;

~~[4.]~~ ***(d)*** Instruction consistent with the current training guidelines of the Centers for Disease Control and Prevention; and

~~[5. A]~~

(e) Except as otherwise provided in subsection 2, a minimum of 20 hours of instruction and ~~[experimental]~~ ***practical*** training concerning:

~~[(a)]~~ ***(1)*** The standards for pediatric, adolescent and adult immunization practices recommended and approved by the United States Public Health Service Advisory Committee on Immunization Practices;

~~[(b)]~~ ***(2)*** Basic immunology, and vaccine and immunization protection;

~~[(c)]~~ ***(3)*** Diseases that are preventable through vaccination and immunization;

~~[(d)]~~ ***(4)*** Recommended immunization schedules;

~~[(e)]~~ ***(5)*** Vaccine and immunization storage and management;

~~[(f)]~~ ***(6)*** Informed consent;

~~[(g)]~~ ***(7)*** Physiology and techniques for administration of immunizations;

~~[(h)]~~ ***(8)*** Preimmunization and postimmunization assessment and counseling;

~~[(i)]~~ ***(9)*** Immunization reporting and records management; and

~~[(j)]~~ ***(10)*** Identification, response, documentation and reporting of adverse events.

2. In lieu of complying with the requirements of paragraph (e) of subsection 1, a pharmacist who administers immunizations consisting exclusively of live attenuated influenza vaccine through the nasal passages of a person may complete a program of less than 20 hours

of instruction which is accredited by the American Council on Pharmaceutical Education and includes instruction relating to:

(a) The epidemiology of influenza;

(b) The pathophysiology, clinical presentation, diagnosis, prevention and treatment of influenza;

(c) The administration, storage and handling of influenza vaccines; and

(d) The counseling of patients who will be immunized with the vaccine.

NOTICE OF ADOPTION OF PROPOSED REGULATION
LCB File No. R187-03

The State Board of Pharmacy adopted regulations assigned LCB File No. R187-03 which pertain to chapter 639 of the Nevada Administrative Code on February 26, 2004

Notice date: 1/8/2004 **Date of adoption by agency:** 2/26/2004
Hearing date: 2/26/2004 **Filing date:** 4/8/2004

INFORMATIONAL STATEMENT

1. A DESCRIPTION OF HOW PUBLIC COMMENT WAS SOLICITED, A SUMMARY OF PUBLIC RESPONSE, AND AN EXPLANATION HOW OTHER INTERESTED PERSONS MAY OBTAIN A COPY OF THE SUMMARY.

   Public comment was solicited through public notices posted in county courthouses and through mailings to interested parties.

   There was no public response expressed relative to this proposed regulation.

2. THE NUMBER OF PERSONS WHO: (A) ATTENDED EACH HEARING; (B) TESTIFIED AT EACH HEARING; AND (C) SUBMITTED TO THE AGENCY WRITTEN STATEMENTS.

   There was no public response expressed relative to this proposed regulation.

3. A DESCRIPTION OF HOW COMMENT WAS SOLICITED FROM AFFECTED BUSINESSES, A SUMMARY OF THEIR RESPONSE, AND AN EXPLANATION HOW OTHER INTERESTED PERSONS MAY OBTAIN A COPY OF THE SUMMARY.

   Comments were solicited from affected businesses through posting of public notices in the county courthouses, by direct mailings to all interested persons who have requested notices of board of pharmacy meeting agendas and by direct mailings to professional and trade associations.

   There was no response from affected businesses relative to this proposed regulation.

4. IF THE REGULATION WAS ADOPTED WITHOUT CHANGING ANY PART OF THE PROPOSED REGULATION, A SUMMARY OF THE REASONS FOR ADOPTING THE REGULATION WITHOUT CHANGE.

   The proposed regulation was adopted without change as no testimony was offered.

5. THE ESTIMATED ECONOMIC EFFECT OF THE REGULATION ON THE BUSINESS WHICH IT IS TO REGULATE AND ON THE PUBLIC. THESE MUST BE STATED SEPARATELY, AND IN EACH CASE MUST INCLUDE:

   A) BOTH ADVERSE AND BENEFICIAL EFFECTS.

   This regulation should have no economic impact on affected businesses or on the public.

   B) BOTH IMMEDIATE AND LONG-TERM EFFECTS.

   This regulation will have no immediate or long-term economic effects on business or the public.

6. THE ESTIMATED COST TO THE AGENCY FOR ENFORCEMENT OF THE PROPOSED REGULATION.

   There will be no additional or special costs incurred by the board for enforcement of this regulation.

7. A DESCRIPTION OF ANY REGULATIONS OF OTHER STATE OR GOVERNMENT AGENCIES WHICH THE PROPOSED REGULATION OVERLAPS OR DUPLICATES AND A STATEMENT EXPLAINING WHY THE DUPLICATION OR OVERLAPPING IS NECESSARY. IF THE REGULATION OVERLAPS OR DUPLICATES A FEDERAL REGULATION, THE NAME OF THE REGULATING FEDERAL AGENCY.

   The Board of Pharmacy is not aware of any similar regulations of other state or government agencies that the proposed regulation overlaps or duplicates.

8. IF THE REGULATION INCLUDES PROVISIONS WHICH ARE MORE STRINGENT THAN A FEDERAL REGULATION WHICH REGULATES THE SAME ACTIVITY, A SUMMARY OF SUCH PROVISIONS.

   The Board of Pharmacy is not aware of any similar regulations of the same activity in which the federal regulation is more stringent.

9. IF THE REGULATION PROVIDES A NEW FEE OR INCREASES AN EXISTING FEE, THE TOTAL ANNUAL AMOUNT THE AGENCY EXPECTS TO COLLECT AND THE MANNER IN WHICH THE MONEY WILL BE USED.

   This regulation does not provide a new or increase of fees.